Skip to content
    TX

    TCG X

    TCG X is a Series B to growth stage investment firm. It has made 5 investments. 40% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (40% of deals). Average disclosed round size is $134.1M (across 5 rounds with reported amounts).

    Find people at TCG X on Goldilocks AI

    Portfolio

    5

    Fund Size

    —

    Top Stage

    Series B

    Last 12 Mo

    0

    Team

    CY

    Chen Yu

    Managing Partner

    SB

    Simon Basseyn

    Investment Team

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    5 investments
    CompanyRoundAmountDate
    UUpstream Bio, Inc.Series B$200MJun 2023
    Plexium logoPlexiumGrowth$102MFeb 2022
    AArtios Pharma LimitedSeries C$153MJul 2021
    RayzeBio logoRayzeBioSeries C$108MJan 2021
    SSynthekine, Inc.Series B$107.5M—

    Top Co-Investors

    Omega Funds3 shared
    Samsara BioCapital3 shared
    RA Capital Management3 shared
    Venrock Healthcare Capital Partners2 shared
    OrbiMed2 shared
    The Column Group2 shared
    Deerfield2 shared
    M Ventures2 shared
    Wellington Management1 shared
    Decheng Capital1 shared
    Enavate Sciences1 shared
    Access Biotechnology1 shared
    Bain Capital Life Sciences1 shared
    HBM Healthcare Investments1 shared
    Canaan Partners1 shared
    Emerson Collective1 shared
    Lilly Asia Ventures1 shared
    Rock Springs Capital1 shared
    Andera Partners1 shared
    RTW Investments, LP1 shared

    Last updated: 19 September 2026